New combo therapy shows promise for Drug-Resistant cancers
NCT ID NCT03474497
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 6 times
Summary
This study tests a combination of three treatments (IL-2 injections, targeted radiation, and the immunotherapy drug pembrolizumab) in adults with advanced lung, skin, kidney, or head and neck cancers that no longer respond to standard immunotherapy. The goal is to see if this triple approach can shrink tumors and control the disease. About 18 participants will receive the therapy, with researchers monitoring safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UC Davis Medical Center
Sacramento, California, 95817, United States
-
University of California Davis Medical Center
Sacramento, California, 97817, United States
Conditions
Explore the condition pages connected to this study.